July 28, 2016 6:49am

… We’ve had a good two day run and three ups from the past five sessions

Too many investors buy when the sector is at a peak and sell during a downturn

… There are risks going long over a summer weekend …

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is today’s market going?  Subscribe and find out! 

 

 

Where do investors turn for insight and perspective - I say truthfully what others won't, so you can do what others can't!

 

 

Companies in the headlights: ADRO, BLCM, JUNO, KITE, KOOL and SGMO

 

Indexes and ETFs: The IBB is NOT indicating, the XLV (-0.12%) and XBI (-0.19%) are DOWN and the IWM (+0.03) is UP

Dow futures are UP +0.08% and NASDAQ futures are UP +0.05%

 

U.S. stock index futures indicated a higher open on Thursday morning as traders eyed a busy day of earnings.

European stocks seesawed as markets digested the latest monetary policy decision from the U.S. Federal Reserve, a raft of earnings and look ahead to the latest decision from the Bank of Japan.

Asia markets closed mixed as investors digested fresh earnings reports and awaited the outcome of the Bank of Japan's (BOJ) two-day policy meeting, due Friday.

Data docket: initial claims and international trade data are due at 8:30 a.m. ET.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Wednesday and Tuesday, NEGATIVE on Monday, POSITIVE on Friday and NEGATIVE last Thursday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Wednesday closed POSITIVE with 15 decliners, 27 advancers and 1 flat
  • Tuesday closed POSITIVE with 13 decliners, 28 advancers and 2 flats;
  • Monday closed NEGATIVE with 25 decliners, 15 advancers and 3 flats;
  • Friday closed POSITIVE with 18 decliners, 22 advancers and 3 flats;
  • Last, Thursday closed NEGATIVE with 22 decliners, 19 advancers and 2 flats;

 

 

Remembering Wednesday’s post, “which side of the trade were you on yesterday? The iShares Nasdaq Biotechnology ETF (IBB) closed 2.4% higher. Will you be on the same side today?

  • My contrarian view, high volatility means less complacency, and lowering complacency could signal, we’ve had better adjust our portfolio.

BUY signals are beginning to conflict <in my eyes> … has a top been recognized?

 

It might just be the time to fold and take your money than to risk going long over a summer weekend …

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Wednesday up +2.41% and is NOT indicating in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Wednesday up +3.01% and is DOWN -0.19% in Thursday’s  pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up Wednesday +0.45% and is DOWN -0.12% in Thursday’s pre-market;
  • The iShares Russell 2000 (IWM) closed up +0.29% on Wednesday and is UP +0.03% in Thursday’s pre-market.

 

 

Companies in my spotlight:

Aduro Biotech (ADRO) closed UP again +$0.67 to $14.93 after Tuesday’s to $14.26 (+$0.06) following Monday’s $14.20 (+$0.20) after Friday’s $14.00 (+$0.33) and after last Thursday’s $13.67 (+$0.44). I sticking to my “numbers” as to trader’s propensity to “finger” the SELL button, lighten the load but, still carry some – Maintaining SELL;

Bellicum Pharma (BLCM) closed UP +$1.52 to $16.38 in yesterday’s <day> range of $14.95 to $16.49 having closed Tuesday at $14.86 and Monday at $14.51 following Friday’s $13.86 and last Thursday’s $13.76. Grab what you can and come back – SELL;

Cesca Therapeutics closed DOWN -$0.57 to $4.40. A - 11.47% drop, after “running the table” to Tuesday’s $4.97 from Monday’s $4.35, last Friday’s $3.14 and Thursday’s $3.08. Take it “off the table”; consolidate position, safety puts money in your pocket - SELL

Juno Therapeutics (JUNO) closed DOWN -$0.15 to $30.37 after Tuesday’s $30.52 (+$1.20) following Monday’s $29.32 (+$0.19) after Friday’s $29.13 (+$0.30) and last Thursday’s $28.83. The aftermarket indication is -$0.07 – Maintaining SELL;

Kite Pharma (KITE) closed UP +$2.23 to $54.243 following Tuesday’s to $52.00 (+$0.49) post Monday’s $51.51 ($0.76). KITE announced an exclusive license with the National Institutes of Health for fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) product candidate to treat B-Cell Malignancies.  KITE has realigned from its pricing drop from Friday’s $50.75 and last Thursday’s $50.18. The aftermarket indication is +$1.02 – BUY;

Sangamo (SGMO) closed UP +$0.51 to $6.34. SGMO is running hot, but steam evaporates. Tuesday’s $5.83 follows Monday’s $5.76 post Friday’s $5.77 and last Thursday’s $5.85. Another one I’d “skim” my gains to come back later - SELL

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.